Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U04 Substudy 04D: Investigational Agents With Enfortumab Vedotin Plus Pembrolizumab in First-Line Urothelial Carcinoma
2025-522253-19-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of pembrolizumab, enfortumab vedotin and MK-3120 in transitional cell carcinoma (TCC) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced At Least One Adverse Event, Number of Participants with Dose-limiting Toxicities and 2 more. Planned start Feb 2026; status: authorised.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2025-522253-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522253-19-00.